A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Trial Profile

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Suspended
Phase of Trial: Phase I

Latest Information Update: 08 May 2017

At a glance

  • Drugs Ipafricept (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 Status changed from active, no longer recruiting to suspended, according to an OncoMed Pharmaceuticals media release.
    • 08 May 2017 According to an OncoMed Pharmaceuticals media release, the company has put this program on hold. OncoMed has subsequently decided to cease dosing patients in the current ipafricept Phase 1b studies following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in the Phase 1b HER2-negative breast cancer trial.
    • 09 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top